DOD Amyotrophic Lateral Sclerosis, Clinical Outcomes and Biomarkers Award

No AI summary available for this file.

The Department of Defense (DOD) is announcing the FY24 Amyotrophic Lateral Sclerosis Research Program (ALSRP) Clinical Outcomes and Biomarkers Award aimed at fostering research to identify and validate clinical outcomes and biomarkers for Amyotrophic Lateral Sclerosis (ALS). The program emphasizes the development of innovative biomarkers and outcome measures related to ALS, potentially enhancing clinical trials and patient care. Applications must adhere to a two-step submission process involving a Pre-Application (Letter of Intent) by June 18, 2024, and a full application by July 10, 2024. Eligibility extends to both extramural and intramural organizations, including academic institutions and for-profit entities, and the maximum budget for funded projects is set at $750,000 with a performance period not exceeding three years. The announcement stresses meaningful community engagement with people who have ALS, emphasizing the role of community partners in research planning and implementation. Applications will be evaluated on scientific merit, research feasibility, clinical impact, and the integration of community perspectives. The initiative reflects a commitment to advancing ALS research through collaboration and innovative approaches that cater directly to the needs of ALS patients and their families.